ISCT, International Society for Cell & Gene Therapy

What ISCT, International Society for Cell & Gene Therapy does

ISCT, International Society for Cell & Gene Therapy, is a US-incorporated 501(c)(3) nonprofit professional society headquartered in Vancouver, BC, Canada. Founded in 1992 as the International Society for Hematotherapy and Graft Engineering (ISHAGE) and later rebranded to reflect its broader CGT scope, ISCT serves a global membership of clinical researchers, physicians, industry professionals, laboratory technologists, and early-career trainees working across the cell and gene therapy translational chain. The society's stated mission is to drive translation of scientific research into safe and effective cellular therapies for patients.

The society operates an integrated portfolio spanning publishing, education, events, and regulatory engagement. Its core intellectual asset is Cytotherapy, the official peer-reviewed journal published with Elsevier (Impact Factor 5.414 in 2020). Membership products include the Telegraft Hub newsletter and the ISCT Online Community, while events include the ISCT annual meeting (Dublin 2026, Toronto 2027, Canada 2028), three regional meetings in 2026 (ANZ Melbourne, Asia Singapore, North America AI Signature Series in Cambridge), and a webinar program. Regulatory and standards work includes the FDA Cell Therapy Liaison Meeting (CTLM), ISCT-AABB Quality Agreement Template, and GTP Interpretative Tool co-developed with FACT and AABB. Workforce development programs include hands-on laboratory bootcamps (e.g., Stanford LCGM) and the inaugural CGT Clinical Applications Program for Fellows at the University of Pennsylvania.

ISCT's revenue model is diversified across tiered membership subscriptions ($55-$185 USD across five tiers, with a 30% discount for World Bank-classified emerging economies), annual and regional meeting registrations, corporate sponsorships and exhibitor fees, and journal subscription revenue. Go-to-market is sales-led and event-driven, leveraging 40+ standing committees, the global event calendar, and digital channels (LinkedIn, X, Bluesky, the isctglobal.org website, and email marketing via Telegraft Hub). The organization has formal strategic alliances with JSRM (Japan, 5-year iPSC collaboration), MIT Center for Biomedical Innovation (AI program), Elsevier (publishing), FACT (accreditation), and AABB (regulatory quality). ISCT does not operate a software product, API, or proprietary technology platform; its technology footprint centers on the HigherLogic membership management platform and Elsevier's publishing infrastructure.

Name

ISCT, International Society for Cell & Gene Therapy

Legal name

ISCT, International Society for Cell & Gene Therapy

Website

https://isctglobal.org

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

ISCT is a US-incorporated 501(c)(3) nonprofit professional society, founded in 1992 and headquartered in Vancouver, that connects a global membership of cell and gene therapy researchers, clinicians, industry professionals, and trainees through the Cytotherapy journal, annual and regional meetings, the Telegraft Hub newsletter, and regulatory standards work.

Ownership category

akta.pro rank

Product category

Professional Association Services

NAICS

Professional Organizations (81392), Business Associations (813910), Newspaper, Periodical, Book, and Directory Publishers (5131), Professional Organizations (813920)

SIC

Services-Membership Organizations (8600), Miscellaneous Publishing (2741), Services-Educational Services (8200)

akta.pro primary industry

Scholarly Societies & Conference Proceedings Publishing (MPAJABAK)

akta.pro secondary industries

Scholarly Society & Association Publishing (EDAGAFAK), Association & Society Conference Management (Nonprofit, Professional Bodies) (THAHACAA), Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ), Medical & Clinical Reference (Physicians, Nursing, Allied Health) (EDAGAGAA)

Keywords

• Cell and gene therapy
• Professional society
• Scientific publishing
• Medical conferences
• Workforce development

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Fees: Annual membership fees from individual members, technologists, advanced practice professionals, residents/fellows/postdocs, and students. Membership calendar year based (January 1 to December 31). Tiered pricing with 30% discount for members in World Bank classified low, low-middle, or upper-middle income countries.
2. Conference and Event Registrations: Revenue from annual meetings, regional meetings, and signature series events through delegate registrations, sponsorships, and exhibitor fees. Events include ISCT 2026 Dublin, ISCT 2027 Toronto, ISCT Asia 2026 Singapore, ISCT ANZ 2026 Melbourne, and North America Regional Signature Series.
3. Publication Revenue: Cytotherapy journal subscription revenue including print version subscriptions at additional cost ($75), with reduced Open Access rates for members. Journal publishes cutting edge findings and clinical trials of cell and gene therapies.
4. Sponsorship and Advertising: Corporate sponsorship recruitment and exhibitor partnerships at conferences and events. Building and maintaining sponsor/supporter profiles for operations and mission advancement.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

ISCT is a global nonprofit professional society that delivers membership services, peer-reviewed scientific publishing (Cytotherapy journal), annual and regional scientific conferences, regulatory guidance resources, and workforce development programs to advance the translation of cell and gene therapies from the laboratory into clinical practice. The society monetizes primarily through tiered individual memberships, event registrations, journal subscriptions, corporate sponsorships, and exhibitor partnerships, serving researchers, clinicians, and industry professionals worldwide.

Product overview

ISCT operates as a professional society offering a unified portfolio of products and services to advance cell and gene therapy translation globally. The core offerings include Cytotherapy, the official peer-reviewed journal publishing cutting-edge CGT research; Telegraft Hub, the member-exclusive monthly newsletter and news platform; ISCT Online Community for member discussions and networking; and ISCT Annual and Regional Meetings providing conference events for knowledge sharing. Supporting these are educational products including webinars, training and development programs (such as hands-on laboratory bootcamps and the CGT Clinical Applications Program for Fellows), and the Career Center job board. ISCT also provides regulatory guidance through initiatives like the Global Regulatory Report, FDA CTLM meetings, Quality Agreement Template, and GTP Interpretive Tool. The society runs thought leadership events including the North America Regional Signature Series on AI, and maintains international research collaborations such as the 5-year ISCT-JSRM Strategic Partnership on Clinical iPSCs. ISCT does not operate a traditional software product with integrations, APIs, or certifications.

Differentiator

Problem solved

Functional benefit

Products and services

• Cytotherapy Journal Official peer-reviewed journal of ISCT publishing cutting edge findings, clinical trials of cell and gene therapies, and news and opinions on all aspects of cell and gene based treatments, focusing especially on practical translation of scientific developments into clinical practice. Subscribed to by researchers, clinicians, and institutions globally.
• ISCT Annual and Regional Meetings Annual scientific meetings (including ISCT 2026 Dublin, ISCT 2027 Toronto) and regional meetings (ISCT Asia 2026 Singapore, ISCT ANZ 2026 Melbourne, North America Regional Signature Series) providing global platforms for knowledge sharing, networking, and abstract presentation among CGT professionals. Sold as paid conference registrations, sponsorships, and exhibitor packages.
• ISCT Webinars Live and on-demand webinar programs providing continuing education on cell and gene therapy topics for CGT professionals, including AI applications in cellular therapy laboratory quality assurance. Sold as standalone or bundled educational programming.
• CGT Clinical Applications Program for Fellows Inaugural educational initiative for clinical fellows interested in cell and gene therapy applications, focusing on advanced CGT applications in hematology/oncology, transplantation, and immune-mediated diseases. First program held October 26-27, 2026 at the University of Pennsylvania.
• ISCT Training and Development Programs Workforce development and professional education programs including hands-on laboratory bootcamps (such as the Stanford LCGM program) and the Cell Therapy Leadership Training Program, sold as fee-based training to CGT professionals.
• ISCT Career Center Member job board providing job postings and career opportunities in the cell and gene therapy field, offered to employers and job-seeking CGT professionals as a paid recruitment service.

Quantifiable outcome

• Cytotherapy 2020 Impact Factor: 5.414
• +2 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Japanese Society for Regenerative Medicine (JSRM)coreStrategic or Co-development Partner · 3 March 2026ISCT and JSRM established a 5-year strategic partnership to advance global development of clinical iPSC therapies. The collaboration focuses on clinical applications, regulatory harmonization, technological innovation, and commercialization. Annual joint events will alternate between the two societies, starting with JSRM's 25th Annual Meeting in Kobe in 2026. The partnership aims to build international standards and frameworks to accelerate safe, effective iPSC therapies reaching patients worldwide.
• MIT Center for Biomedical InnovationcoreStrategic or Co-development PartnerDeveloped collaboration on the 2026 ISCT North America Regional Signature Series exploring AI applications in cell and gene therapy manufacturing, quality systems, analytics, clinical applications, and collaborative data ecosystems. The program bridges innovation with practical implementation.
• ElseviercoreStrategic or Co-development PartnerElsevier serves as publisher for Cytotherapy, the official peer-reviewed journal of ISCT. The journal publishes cutting edge findings, clinical trials of cell and gene therapies, and news on all aspects of the rapidly expanding field of cell and gene based treatments.
• FACT (Foundation for the Accreditation of Cellular Therapy)coreStrategic or Co-development PartnerFACT accreditation standards and education programs are promoted through ISCT. FACT and ISCT collaborate on educational initiatives including FACT Education programs empowering quality and safety professionals in cellular therapy.
• AABBcoreStrategic or Co-development PartnerISCT and AABB collaborate on regulatory quality initiatives including the ISCT-AABB Quality Agreement Template and ISCT-AABB GTP Interpretative Tool for Good Tissue Practice compliance.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• European Society for Blood and Marrow Transplantation (EBMT): EBMT is the European professional society for blood and marrow transplantation and cellular therapy. Its annual meeting and clinical working parties overlap significantly with ISCT's hematology/oncology and transplantation-focused clinical translation work.
• Tissue Engineering and Regenerative Medicine International Society (TERMIS): TERMIS is a global scientific society for tissue engineering and regenerative medicine with regional chapters (Americas, Europe, Asia-Pacific). It targets a closely overlapping translational research community and competes with ISCT for sponsors, speakers, and delegates.
• Japanese Society for Regenerative Medicine (JSRM): JSRM is ISCT's Japanese counterpart in regenerative medicine and a 5-year strategic partner on clinical iPSC therapies. It convenes an overlapping translational research and clinical community, particularly in Asia-Pacific.
• International Society for Experimental Hematology (ISEH): ISEH is a global scientific society for experimental hematology, with significant overlap in cell therapy, stem cell, and transplantation research communities. Its annual meeting and journal compete for similar scientific content and members.
• International Society for Stem Cell Research (ISSCR): ISSCR is the global professional society for stem cell research, with overlapping membership from the regenerative medicine and cell therapy research community. Its annual meeting and guidelines work compete directly with ISCT's content and events in adjacent CGT domains.
• Foundation for the Accreditation of Cellular Therapy (FACT): FACT sets cellular therapy accreditation standards and runs joint educational initiatives with ISCT. It targets the same cellular therapy labs, manufacturing facilities, and clinical programs, making it a closely allied but functionally overlapping peer.
• American Society of Gene & Cell Therapy (ASGCT): ASGCT is the leading US-based professional society for gene and cell therapy researchers and clinicians. It is the most direct peer to ISCT, competing for the same CGT researchers, clinicians, and industry sponsors across overlapping annual meetings and scientific committees.

Emerging players

• International Society for Biological and Environmental Repositories (ISBER): ISBER is a global society for biobanking and biorepository best practices, including cell and tissue repositories used in CGT. It addresses an adjacent but partially overlapping community of laboratory and manufacturing professionals.

Broad incumbents

• AABB: AABB is a larger, established US-based association for blood and biotherapies, and a strategic partner to ISCT on regulatory and quality initiatives. It serves a broader portfolio that overlaps with ISCT's cellular therapy work but extends into traditional transfusion medicine.
• International Society of Blood Transfusion (ISBT): ISBT is the global scientific society for blood transfusion and related cellular therapies. While broader than ISCT, it serves an overlapping member base in transfusion medicine, cellular therapy manufacturing, and quality/regulatory practice.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/isctglobal
• LinkedInlinkedin.com/company/isctglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ISCT, International Society for Cell & Gene Therapy